Cassava Sciences (NASDAQ: SAVA) witnessed a dramatic surge in its stock price today, climbing an impressive 18% after its President and CEO, Richard Barry, disclosed a significant personal investment in the company. The move, which saw Barry acquire hundreds of thousands of shares, has injected a much-needed dose of confidence
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Cassava Sciences shares are trading higher Tuesday morning. A Form 4 filing disclosed that CEO Rick Barry acquired 237,941 shares at an average price of $2.25 each.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by the end of the second quarter of 2025.
Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January.
Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market.
Stocks are a mixed bag this afternoon, with the S&P 500 Index and Nasdaq Composite earlier touching fresh record highs as the latter jumps triple digits.
